Powerful vascular protection by combining cilnidipine with valsartan in stroke-prone, spontaneously hypertensive rats
Open Access
- 29 November 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Hypertension Research
- Vol. 36 (4), 342-348
- https://doi.org/10.1038/hr.2012.187
Abstract
Cilnidipine is an L- and N-type calcium channel blocker (CCB), and amlodipine is an L-type CCB. Valsartan (10 mg kg−1), valsartan (10 mg kg−1) and amlodipine (1 mg kg−1), and valsartan (10 mg kg−1) and cilnidipine (1 mg kg−1) were administered once daily for 2 weeks to stroke-prone, spontaneously hypertensive rats (SHR-SPs). Blood pressure was significantly reduced by valsartan, and it was further reduced by the combination therapies. Vascular endothelial dysfunction was significantly attenuated in all therapeutic groups, and further significant attenuation was observed in the valsartan+cilnidipine-treated group, but not in the valsartan+amlodipine-treated group. Vascular nicotinamide adenine dinucleotide phosphate (NADPH) oxidase subunit NOX1 gene expression was significantly attenuated in all therapeutic groups, and significantly greater attenuation was observed in the valsartan+cilnidipine-treated group than in the valsartan-treated group. Compared with the valsartan-treated group, the positive areas for 4-hydroxy-2-nonenal were significantly lower only in the valsartan+cilnidipine-treated group. Plasma renin activity was significantly augmented in the valsartan-treated group, and it was significantly attenuated in the valsartan+cilnidipine-treated group. A significant increase in the ratio of plasma angiotensin-(1-7) to angiotensin II was observed only in the valsartan+cilnidipine-treated group. Vascular angiotensin-converting enzyme (ACE) gene expression was significantly attenuated only in the valsartan+cilnidipine-treated group, but ACE2 gene expression was significantly higher in all of the therapeutic groups. Thus, valsartan and cilnidipine combination therapy might have a powerful protective effect in the vascular tissues via increases in the angiotensin-(1-7)/angiotensin II ratio in plasma.Keywords
This publication has 38 references indexed in Scilit:
- Effects of an N-Type Calcium Antagonist on Angiotensin II-Renin FeedbackAmerican Journal of Nephrology, 2011
- Candesartan and amlodipine combination therapy provides powerful vascular protection in stroke-prone spontaneously hypertensive ratsHypertension Research, 2010
- Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive ratsHypertension Research, 2010
- Significance of angiotensin II receptor blockers with high affinity to angiotensin II type 1 receptors for vascular protection in ratsHypertension Research, 2009
- Endothelial Dysfunction and Elevated Blood Pressure in Mas Gene-Deleted MiceHypertension, 2008
- Upregulation of Angiotensin-Converting Enzyme 2 After Myocardial Infarction by Blockade of Angiotensin II ReceptorsHypertension, 2004
- Calcium Channel Blocker Azelnidipine Enhances Vascular Protective Effects of AT 1 Receptor Blocker OlmesartanHypertension, 2004
- Bradykinin Potentiation by Angiotensin-(1-7) and ACE Inhibitors Correlates With ACE C- and N-Domain BlockadeHypertension, 2001
- Superoxide Anion Production Is Increased in a Model of Genetic HypertensionHypertension, 1999
- Angiotensin-(1-7) Dilates Canine Coronary Arteries Through Kinins and Nitric OxideHypertension, 1996